news
Five HERV expression signatures linked to psychiatric disorders
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
List view / Grid view
Depression
news
New therapeutic targets for stress related disorders
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
article
Growth hormone’s influence on neuropsychiatric disorders
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
news
Novel AI algorithm improves decoding accuracy of brain signals
A new deep-learning method could enhance therapeutic devices for people with neurological or mental health conditions.
news
Scientists discover multiple pathways of the 5HT2a receptor activated by psychedelics
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
article
Innovative treatments: the new frontier for mental health
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
news
Intranasal drug may be the future of depression treatments
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
news
Multi-omics approach identifies genes associated with alcohol use disorder
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
news
Common antidepressant drugs fight cancer in mice, study shows
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
news
Non-hallucinogenic version of ibogaine could treat addiction and depression
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
news
New insight to guide discovery of drugs targeting ion channels
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
news
Novel antibody treatment for OCD demonstrates efficacy in mice
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
news
New compound could alleviate side effects of antidepressant drugs
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
article
Safer and more affordable medicine for all? How pharmacogenomics may level the playing field
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.